Enabling Innovation
in Latin America.

Focused on meeting Life Science needs in Latin America.

Opportunity
Assessment

We help our clients to understand the size and feasibility of the opportunity, determine the appropriate level of investment, identify the associated risks and estimate related times for each strategic option.

Strategic Definition
& Plan Formulation

We assist our clients to formulate the business development strategy and plan for a successful execution. Whether is a startup, an out-licensing or a distribution, we leverage our knowledge and connections.

Execution

Upon our clients’ request, we can also support full scale due diligence, deal negotiation and closing, assist with the transitioning process and provide alliance management services.

Latin America is a large, diverse and complex region with a fast-growing healthcare sector that requires the right set of experience and skills to succeed.

  • More than 650M people living in more than 20 countries
  • A $50B sector growing 2x faster than in the developed regions
  • Diverse regulation, access, pricing and reimbursement processes.
  • Fluctuant economic and political environment

Focused on meeting Life Science needs in Latin America.

We are a consulting firm highly experienced and exclusively focused on meeting the needs of life science companies in and for Latin America.

We have a vast expertise and hands-on experience in the region. We count with an extensive network of global life science companies.

We have a wide expereince on crafting partnerships. Our team has assisted more than 30 multinational and regional pharmaceutical companies in closing licensing, distribution, Co-Promotion and M&A deals in Latin America

+0
Numbers of companies assisted
+0
Numbers of molecules in/out-licensed in the region
+0
Numbers of deals in the region

“…More than 40% of the molecules that are approved every year by the FDA and EMA will never be commercialized in Latin America.
Beyond Parallel 32 was born with the purpose of closing this gap and making more innovative medicines available for patients in the region…”

Managing Director • Beyond Parallel 32